, Tracking Stock Market Picks
Enter Symbol:
Genomic Health, Inc. (GHDX) [hlAlert]

up 52.48 %

Genomic Health, Inc. (GHDX) rated Overweight with price target $23 by Thomas Weisel

Posted on: Thursday,  Jun 11, 2009  8:25 AM ET by Thomas Weisel

Thomas Weisel rated Overweight Genomic Health, Inc. (NASDAQ: GHDX) on 06/11/2009, when the stock price was $17.53. Since
then, Genomic Health, Inc. has gained 52.48% as of 01/06/2016's recent price of $26.73.
If you would have followed this Thomas Weisel's recommendation on GHDX, you would have gained 52.48% of your investment in 2400 days.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

At Thomas Weisel Partners, the role of Research is to contribute to our clients' decision process in ways that lead to better investment decisions. We cover the key growth sectors of the economy including Consumer, Energy, Financial Services, Healthcare, Internet, Media & Telecom, Metals & Mining and Technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/11/2009 8:25 AM Buy
17.53 23.00
as of 12/31/2009
1 Week up  3.55 %
1 Month up  13.51 %
3 Months down  -1.28 %
1 YTD up  23.10 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy